Form 4: Aquestive Therapeutics Executive Stephen Wargacki Reports Stock Transactions

Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, reports acquisition and disposal of company stock and stock options.

Summary

• On March 7, 2025, Stephen Wargacki, Chief Science Officer of Aquestive Therapeutics, acquired 115,000 shares of common stock and disposed of 12,859 shares to cover tax obligations.
• The acquisition of 115,000 shares was at a price of $0.
• The disposal of 12,859 shares was at a price of $2.65.
• On March 9, 2025, Wargacki disposed of 15,431 shares at $2.65 to cover tax obligations.
• On March 10, 2025, Wargacki disposed of 4,572 shares at $2.54 to cover tax obligations.
• Wargacki also acquired 65,000 non-qualified stock options with an exercise price of $2.65, expiring on March 7, 2035.
• Following these transactions, Wargacki directly owns 343,552 shares of Aquestive Therapeutics common stock and 65,000 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment. This is a routine disclosure of stock transactions by a company executive. The acquisition of shares is mildly positive, but the disposal to cover taxes is a normal occurrence.

Positives

• The acquisition of 115,000 shares by the Chief Science Officer could be seen as a positive signal, indicating confidence in the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting or increasing the share float.

Key Dates